119 related articles for article (PubMed ID: 15620440)
21. Predicting hospital rates of fluoroquinolone-resistant Pseudomonas aeruginosa from fluoroquinolone use in US hospitals and their surrounding communities.
Polk RE; Johnson CK; McClish D; Wenzel RP; Edmond MB
Clin Infect Dis; 2004 Aug; 39(4):497-503. PubMed ID: 15356812
[TBL] [Abstract][Full Text] [Related]
22. The incidence of fluoroquinolone resistant infections after prostate biopsy--are fluoroquinolones still effective prophylaxis?
Feliciano J; Teper E; Ferrandino M; Macchia RJ; Blank W; Grunberger I; Colon I
J Urol; 2008 Mar; 179(3):952-5; discussion 955. PubMed ID: 18207185
[TBL] [Abstract][Full Text] [Related]
23. Correlation between fluoroquinolone consumption in hospitals and ciprofloxacin resistance amongst Pseudomonas aeruginosa isolates causing healthcare-associated infections, Taiwan, 2000-2009.
Weng TC; Chen YH; Lee CC; Wang CY; Lai CC; Tang HJ; Ko WC; Hsueh PR
Int J Antimicrob Agents; 2011 Jun; 37(6):581-4. PubMed ID: 21489757
[No Abstract] [Full Text] [Related]
24. Methicillin-resistant Staphylococcus aureus prolongs intensive care unit stay in ventilator-associated pneumonia, despite initially appropriate antibiotic therapy.
Shorr AF; Combes A; Kollef MH; Chastre J
Crit Care Med; 2006 Mar; 34(3):700-6. PubMed ID: 16505656
[TBL] [Abstract][Full Text] [Related]
25. Five years of nosocomial Gram-negative bacteremia in a general intensive care unit: epidemiology, antimicrobial susceptibility patterns, and outcomes.
Sligl W; Taylor G; Brindley PG
Int J Infect Dis; 2006 Jul; 10(4):320-5. PubMed ID: 16460982
[TBL] [Abstract][Full Text] [Related]
26. Contribution of clonal dissemination and selection of mutants during therapy to Pseudomonas aeruginosa antimicrobial resistance in an intensive care unit setting.
Juan C; Gutiérrez O; Oliver A; Ayestarán JI; Borrell N; Pérez JL
Clin Microbiol Infect; 2005 Nov; 11(11):887-92. PubMed ID: 16216103
[TBL] [Abstract][Full Text] [Related]
27. Bacteriostatic and bactericidal activities of eight fluoroquinolones against MexAB-OprM-overproducing clinical strains of Pseudomonas aeruginosa.
Dupont P; Hocquet D; Jeannot K; Chavanet P; Plésiat P
J Antimicrob Chemother; 2005 Apr; 55(4):518-22. PubMed ID: 15722391
[TBL] [Abstract][Full Text] [Related]
28. Epidemiology, risk factors and outcome of nosocomial infections in a Respiratory Intensive Care Unit in North India.
Agarwal R; Gupta D; Ray P; Aggarwal AN; Jindal SK
J Infect; 2006 Aug; 53(2):98-105. PubMed ID: 16343637
[TBL] [Abstract][Full Text] [Related]
29. Antimicrobial resistance in nosocomial bloodstream infection associated with pneumonia and the value of systematic surveillance cultures in an adult intensive care unit.
Depuydt PO; Blot SI; Benoit DD; Claeys GW; Verschraegen GL; Vandewoude KH; Vogelaers DP; Decruyenaere JM; Colardyn FA
Crit Care Med; 2006 Mar; 34(3):653-9. PubMed ID: 16505649
[TBL] [Abstract][Full Text] [Related]
30. Induction of resistance to fluoroquinolones in clinical and environmental isolates of Pseudomonas aeruginosa.
Prasad SV; Ballal M; Shivananda PG
Indian J Pathol Microbiol; 2007 Jan; 50(1):94-6. PubMed ID: 17474274
[TBL] [Abstract][Full Text] [Related]
31. [Infectivity and resistance to antibiotics of bacterial strains isolated from patients hospitalised in intensive care units].
Wojnicz D; Korzekwa K; Kakol A; Doroszkiewicz W
Med Dosw Mikrobiol; 2007; 59(1):75-84. PubMed ID: 17601034
[TBL] [Abstract][Full Text] [Related]
32. [Low-level resistance to fluoroquinolones conferred by efflux overproduction in Pseudomonas aeruginosa: clinical significance and routine detection].
Hocquet D; Patry I; Dupont P; Bize M; Jeannot K; Chavanet P; Plésiat P
Pathol Biol (Paris); 2005; 53(8-9):495-9. PubMed ID: 16203109
[TBL] [Abstract][Full Text] [Related]
33. Nosocomial outbreak by imipenem-resistant metallo-beta-lactamase-producing Pseudomonas aeruginosa in an adult intensive care unit in a Brazilian teaching hospital.
Cezário RC; Duarte De Morais L; Ferreira JC; Costa-Pinto RM; da Costa Darini AL; Gontijo-Filho PP
Enferm Infecc Microbiol Clin; 2009 May; 27(5):269-74. PubMed ID: 19386392
[TBL] [Abstract][Full Text] [Related]
34. Reducing empirical use of fluoroquinolones for Pseudomonas aeruginosa infections improves outcome.
Nguyen LH; Hsu DI; Ganapathy V; Shriner K; Wong-Beringer A
J Antimicrob Chemother; 2008 Mar; 61(3):714-20. PubMed ID: 18222951
[TBL] [Abstract][Full Text] [Related]
35. Comparison of in vitro activities of levofloxacin, ciprofloxacin, ceftazidime, cefepime, imipenem, and piperacillin-tazobactam against aerobic bacterial pathogens from patients with nosocomial infections.
Huang SS; Lee SC; Lee N; See LC; Tsai MH; Shieh WB
J Microbiol Immunol Infect; 2007 Apr; 40(2):134-40. PubMed ID: 17446961
[TBL] [Abstract][Full Text] [Related]
36. Investigation of a nosocomial outbreak by alginate-producing pan-antibiotic-resistant Pseudomonas aeruginosa.
Yakupogullari Y; Otlu B; Dogukan M; Gursoy C; Korkmaz E; Kizirgil A; Ozden M; Durmaz R
Am J Infect Control; 2008 Dec; 36(10):e13-8. PubMed ID: 19084158
[TBL] [Abstract][Full Text] [Related]
37. Association between fluoroquinolone usage and a dramatic rise in ciprofloxacin-resistant Streptococcus pneumoniae in Canada, 1997-2006.
Adam HJ; Hoban DJ; Gin AS; Zhanel GG
Int J Antimicrob Agents; 2009 Jul; 34(1):82-5. PubMed ID: 19342204
[TBL] [Abstract][Full Text] [Related]
38. Device-associated hospital-acquired infection rates in Turkish intensive care units. Findings of the International Nosocomial Infection Control Consortium (INICC).
Leblebicioglu H; Rosenthal VD; Arikan OA; Ozgültekin A; Yalcin AN; Koksal I; Usluer G; Sardan YC; Ulusoy S;
J Hosp Infect; 2007 Mar; 65(3):251-7. PubMed ID: 17257710
[TBL] [Abstract][Full Text] [Related]
39. Microbiologic spectrum and susceptibility pattern of clinical isolates from the pediatric intensive care unit in a single medical center - 6 years' experience.
Lee CY; Chen PY; Huang FL; Lin CF
J Microbiol Immunol Infect; 2009 Apr; 42(2):160-5. PubMed ID: 19597649
[TBL] [Abstract][Full Text] [Related]
40. The effect of limiting antimicrobial therapy duration on antimicrobial resistance in the critical care setting.
Marra AR; de Almeida SM; Correa L; Silva M; Martino MD; Silva CV; Cal RG; Edmond MB; dos Santos OF
Am J Infect Control; 2009 Apr; 37(3):204-9. PubMed ID: 18986735
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
